Incidence and factors associated with genitourinary infections among Type 2 diabetes patients on SGLT2 Inhibitors: A single retrospective cohort study - 06/07/22
, Elaine C. Cunanan, Sjoberg A. Kho
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Genitourinary infections are quite common among diabetic patients, and some studies suggest that the use of SGLT2 inhibitors further increases this potential risk |
• | The 3 and 6 month incidence of genitourinary infections among type 2 diabetics is higher with dapagliflozin and empagliflozin. |
• | Factors associated with genitourinary infection among Type 2 diabetics on SGLT2 and include HbA1c of ≥7.0%, and concomitant insulin and/or SUR use signifying poorly controlled diabetes. Same factors were linked with genital infection alone, along with diabetes duration of >10 years and overweight/obese BMI. Factors associated with UTI alone include elevated Hba1c and eGFR of <60 ml/min. |
Abstract |
Aims |
To determine the incidence and factors associated with genitourinary infection among patients with type 2 diabetes on SGLT2 inhibitors.
Methods |
This was a retrospective cohort study that included 253 patients with type 2 diabetes who were on SGLT2 inhibitors from January 1, 2014 to June 30, 2019. Multiple logistic regression analysis was used to determine the factors associated with genitourinary infections.
Results |
3 and 6-month incidences of genitourinary infections were 2.37% and 21.78%, respectively. Factors associated with genitourinary infections include HbA1c levels of ≥7.0 to <8.0% (OR=3.45; p=0.001), ≥8.0 to <9.0% (OR=8.56; p<0.0001), ≥9.0% (OR=11.45; p<0.0001), and concomitant sulfonylurea (SUR) (OR=4.13; p<0.001), and insulin (OR= 3.81; p<0.001) use. These factors were also associated with genital infection alone, in addition to overweight/obese BMI (OR=2.42; p=0.039) and diabetes duration of >10 years (OR=1.98; p=0.026). Factors associated with UTI alone were Hba1c levels of ≥8.0 to <9.0%, (OR=3.18; p=0.002) and ≥9.0% (OR=2.48; p=0.008) and eGFR of 30–60 ml/min (OR=2.94; p=0.003)
Conclusion |
Genitourinary infection is common among patients on SGLT2 inhibitors within 6 months of treatment. Factors associated with genitourinary infections vary by gender and include HbA1c of ≥7.0%, and concomitant insulin and/or SUR use . Same factors were linked with genital infection alone, along with diabetes duration of >10 years and overweight/obese BMI. Factors associated with UTI alone include elevated Hba1c and eGFR of <60 ml/min.
Le texte complet de cet article est disponible en PDF.Keywords : SGLT2 inhibitors, UTI risk factors, Type 2 Diabetes
Plan
Vol 7
Article 100082- juillet 2022 Retour au numéro
Article précédent
- Is REmogliflozin an effective Drug in MANaging Type-2 diabetes mellitus: A comparative study – (REDMAN)
- Prabhat Agrawal, Nikhil Pursnani, Ashish Gautam, Ruchika Garg
- Utilization of emergency services for severe hypoglycemia in people with diabetes in France: A study based on the national health insurance database
- Florence Chartier, Louis Soulat, Imane Benabbad, Hélène Sapin, Lyse Bordier, Alexandre Vainchtock, Fanny Raguideau, Roland Cash
Bienvenue sur EM-consulte, la référence des professionnels de santé.